Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

ovarian neoplasms/fatigue

リンクがクリップボードに保存されます
ページ 1 から 442 結果

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Few data are available on long-term fatigue (LTF) and quality of life (QoL) among epithelial ovarian cancer survivors (EOCS). In this case-control study, we compared LTF, symptoms and several QoL domains in EOCS relapse-free ≥3years after first-line treatment and age-matched healthy
OBJECTIVE There are few studies of somatic and mental morbidity in epithelial ovarian cancer survivors (EOCSs). The aim of this controlled, cross-sectional study was to explore fatigue, quality of life (QOL), and somatic and mental morbidity in EOCSs. METHODS Among 287 EOCSs treated according to

Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: a review of contributing factors.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Women diagnosed with stage III or IV ovarian cancer typically are treated with surgery followed by chemotherapy. Intraperitoneal (IP) chemotherapy, the direct administration of chemotherapy into the IP cavity, has been explored as a viable treatment option for some women with advanced ovarian

The trajectory of fatigue in adult patients with breast and ovarian cancer receiving chemotherapy.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE To describe the trajectory of fatigue and determine the feasibility of exploring physiologic mechanisms of fatigue in adult patients receiving chemotherapy for breast and ovarian cancer. METHODS Descriptive, longitudinal, repeated measures. METHODS Outpatient ambulatory cancer centers

Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Risk-reducing salpingo-oophorectomy (RRSO) is the safest intervention for prevention of ovarian cancer in women at increased risk for hereditary breast-ovarian cancer. Little is known about other effects of RRSO. The objective of this study was to investigate quality of life (QoL) and

Disease-free ovarian cancer patients report severe pain and fatigue over time: prospective quality of life assessment in a consecutive series.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
objective: Among ovarian cancer patients, cancer treatment is aggressive and yet survival is often so limited; hence, this study sought to measure quality of life with the ultimate goal of identifying ways of improving it over the duration of these patients' lives. METHODS The medical records of all
BACKGROUND High levels of fatigue have been documented in ovarian cancer patients. However, increased levels of fatigue are positively associated with a high risk of sleep disturbance and depression. OBJECTIVE To investigate the feasibility of a nurse-led home-based exercise and cognitive behavioral
Elevations in the pro-inflammatory cytokine interleukin-6 (IL-6) and alterations in the anti-inflammatory hormone cortisol have been reported in a variety of cancers. IL-6 has prognostic significance in ovarian cancer and cortisol has been associated with fatigue, disability, and vegetative

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Few data are available on long-term fatigue (LTF) and quality of life (QoL) among epithelial ovarian cancer survivors (EOCS). In this case-control study, we compared LTF, symptoms and several QoL domains in EOCS relapse-free ≥3 years after first-line treatment and age-matched healthy

Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Pro-inflammatory cytokines, such as interleukin-6 (IL-6), have been implicated in the underlying processes contributing to sleep regulation and fatigue. Despite evidence for sleep difficulties, fatigue, and elevations in IL-6 among women with ovarian cancer, the association between these symptoms

Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Physical activity has been associated with better health-related outcomes in several cancer survivor groups but very few data exist for women with ovarian cancer. The purpose of this study was to investigate the associations between physical activity and health-related outcomes in ovarian cancer

Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Diagnosis and treatment of ovarian cancer (OC) entail severe symptom burden and a significant loss of quality of life (QOL). Somatic and psychological impairments may persist well beyond active therapy. Although essential for optimal symptom management as well as for the interpretation of

Auricular acupressure: reducing side effects of chemotherapy in women with ovarian cancer.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Many women with ovarian cancer may experience adverse effects from adjuvant chemotherapy after surgery. Non-pharmacological interventions can be used to reduce these side effects. We tested auricular acupressure to reduce treatment side effects in this

Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE The aim of this study was to investigate the efficacy and safety of intraperitoneal catumaxomab in heavily pretreated patients with chemotherapy-refractory ovarian cancer and recurrent symptomatic malignant ascites. METHODS The study is a single-arm open-label multicenter US phase II

Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge